IJO International Journal of Oncology 1019-6439 1791-2423 D.A. Spandidos 10.3892/ijo.2012.1539 ijo-41-03-1029 Articles Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab LVSHASHA1 TEUGELSERIK1 SADONESJAN12 DE BRAKELEERSYLVIA1 DUERINCKJOHNNY14 FOURSTEPHANIE DU14 MICHOTTEALEX23 DE GRÈVEJACQUES1 NEYNSBART1 Laboratory of Molecular Oncology and Department of Medical Oncology, Departments of Pathology, Pathology and Neuropathology and Neurosurgery, University Hospital Brussels, Free University Brussels, 1090 Brussels, Belgium Correspondence to: Dr Bart Neyns, Medical Oncology, University Hospital Brussels, Free University Brussels, Laarbeeklaan 101, 1090 Brussels, Belgium, E-mail: bart.neyns@uzbrussel.be 9 2012 29 06 2012 41 3 1029 1035 09 03 2012 27 04 2012 Copyright © 2012, Spandidos Publications 2012 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

Mutation and gene amplification of the epithelial growth factor receptor (EGFR) is one of the most common genetic alterations in glioblastoma (GB). EGFR is, therefore, an attractive molecular target for the treatment of GB. EGFR-targeted therapies however have been largely ineffective in clinical trials. In this study, we investigated the correlation between the EGFR gene amplification status, expression of the EGFR variant III (EGFRvIII) and EGFR variant IV (EGFRvIV) mutations, expression of the phosphatase and tensin homologue gene on chromosome 10 (PTEN) and mutation of the isocitrate dehydrogenase 1 (IDH1) gene and the survival of patients suffering from recurrent glioblastoma who were treated with the EGFR-targeted monoclonal antibody cetuximab in a prospective phase II clinical trial. EGFR amplification was detected in 19 out of 35 GB (54%), EGFRvIII expression in 11 (31.4%) and EGFRvIV expression in 7 (20%). The EGFRvIII and EGFRvIV mutations were exclusively found in GB with EGFR amplification and were almost mutually exclusive with IDH1 mutation (EGFRvIII mutation was found in 1 out of 11 GB with an IDH1 mutation). Patients with an EGFR amplification lacking EGFRvIII expression had a significantly superior progression free survival (PFS) and a numerical better overall survival (OS) following treatment with cetuximab [median PFS 3.03 vs. 1.63 months (p=0.006); median OS 5.57 vs. 3.97 months (p= 0.12)]. Within the subgroup of patients with EGFR amplification, patients with EGFRvIII positive glioblastoma had a worse survival [median PFS 1.63 vs. 3.03 months (p=0.01); median OS 3.27 vs. 5.57 months (p=0.08)]. Our observations indicate that the type of EGFR mutation may determine the outcome of GB patients treated with cetuximab. Prospective investigation of both the EGFR amplification and mutation status in clinical trials with EGFR-targeted therapies for GB is indicated.

 epithelial growth factor receptor amplification epithelial growth factor receptor variant III epithelial growth factor receptor variant IV isocitrate dehydrogenase 1 phosphatase and tensin homologue gene on chromosome 10 glioblastoma cetuximab Introduction

Glioblastoma (GB, WHO grade IV glioma) and anaplastic gliomas (WHO grade III gliomas) are lethal brain tumors for which only limited therapeutic options exist. The standard treatment for high-grade gliomas (WHO grade III and IV) consists of a maximal safe surgical resection followed by adjuvant radiotherapy. While concomitant temozolomide during the radiation therapy followed by six cycles of adjuvant chemotherapy improves the survival of patients with GB, the role of chemotherapy in the initial treatment of anaplastic glioma remains to be defined (1).

Clinically relevant molecular subtypes of GB have recently been identified (2). A small proportion of GB are characterized by mutation of the isocitrate dehydrogenase 1 and −2 (IDH1 and −2) genes, a genotype that is most frequently found in low-grade and anaplastic gliomas (3). Genomic alterations of the epidermal growth factor receptor (EGFR) gene play a crucial role in pathogenesis of a subgroup of GB (4). The most common gain-of-function alterations for EGFR in GB are mutation, amplification, and overexpression (5,6). Expression of a constitutively phosphorylated EGFR-mutant, EGFR variant III (EGFRvIII), is found in approximately 20%–30% of GB patients. EGFRvIII has an in-frame deletion of exons 2–7 resulting in the loss of the amino acid residues that contribute to the ligand binding area. Consequently, EGFRvIII causes ligand-independent constitutive activation of downstream signaling pathways such as the Mitogen-activated protein kinase (MAPK) pathway that contributes to the malignant phenotype (7–9). In vitro studies have demonstrated that expression of EGFRvIII leads to a growth and survival advantage in several types of cancer cells (10–13). Another frequent EGFR mutant in GB is the EGFR variant IV (EGFRvIV), which has a genomic truncation of the carboxyl-terminus domain (CTD, exon 25, 26 and 27 in EGFRvIVa or exon 25 and 26 in EGFRvIVb) (14,15). Both EGFRvIV variants have a transforming capacity in vitro and in animals (16). Furthermore, a novel deletion mutation with the transforming capacity was found also in EGFR CTD which is the deletion of exon 27 (17).

In high-grade gliomas, the EGFRvIII and EGFRvIV mutations have been found exclusively in association with EGFR gene amplification (18,19). Expression of EGFRvIII identifies a particular subtype of anaplastic astrocytoma with a poor prognosis. In the global GB-population this correlation with survival is less distinct (20–24). However, within the subpopulation of GB patients with EGFR amplification, a strong correlation was reported between EGFRvIII expression and a poor overall survival (4). No study has yet reported a correlation between EGFRvIV expression and survival of GB patients.

The importance of EGFRvIII expression as a predictive marker for anti-EGFR therapies has been a matter of debate. Co-expression of EGFRvIII and a phosphatase and tensin homologue on chromosome 10 (PTEN) was reported to be a significant predictor of responsiveness to small molecule EGFR kinase inhibitors in retrospectively identified GB patients benefitting from such therapy (25). Furthermore, concomitant EGFRvIII expression and loss of PTEN were shown to synergistically induce genomic instability in vitro and result in enhanced tumor formation (26). In additional studies it was reported that EGFR amplification and protein kinase B/akt activation to predict the response to treatment with a small molecule EGFR kinase inhibitor in GB patients (27–28). These findings were however not confirmed in a prospective randomized study with erlotinib (29).

In vitro data indicate that cetuximab is able to bind to and down regulate EGFRvIII. This may however not be sufficient to inhibit the proliferation of the glioma cells (30). Other observations have indicated that cetuximab not only reduced the phosphorylated EGFRvIII but also inhibited significantly the proliferation of EGFRvIII expressing cells (31). Moreover, cetuximab proved to be active in animal models with EGFR amplified GB (32). In addition, radiation and chemotherapeutic agents augmented the effect of cetuximab on GB cells in vitro and in vivo (33). Recently, the anti-tumor activity of cetuximab against EGFR CTD-mutant GB in both cells and animals was reported (17).

We have previously reported the results of a stratified 2-arm prospective phase II clinical trial of recurrent high-grade glioma patients treated with the EGFR monoclonal antibody cetuximab. A numerically superior outcome, not reaching statistical significance, was found in patients with EGFR gene amplification (34). In this work, we have further investigated the correlation between EGFR amplification, EGFRvIII and EGFRvIV expression, PTEN expression, and IDH1 mutation status and the survival of patients treated with cetuximab in this clinical trial.

 Materials and methods Patients and tumor material

Tumor material was obtained from 35 patients with recurrent high-grade glioma who participated in the prospective phase II trial (34). Tumor tissues were obtained during therapeutic resections performed before the time of study participation. Tumor sections with a thickness of 4 μm were used for H&E staining and centralized review of tumor histopathology and grading according to WHO 2007 criteria (35).

 EGFR and IDH1 molecular analysis

The IDH1 mutation status was assessed with a PCR-DGGE-Sequencing system as reported previously (36). The amplification status of EGFR was assessed by FISH, as described in the report on the clinical trial with cetuximab (34).

For the molecular analysis of EGFRvIII, formalin-fixed paraffin-embedded (FFPE) tissue blocks were sectioned at a thickness of 10 μm (3 sections for RNA isolation). As a positive control an EGFRvIII transfected U87 cell line, obtained from Professor Webster Cavenee (Ludwig Institute for Cancer Research, University of California, San Diego, CA, USA), was used (10). Tissues were dewaxed by xylene and ethanol. The total RNA was isolated from tumor sections using the RNeasy FFPE kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions with modifications by changing the incubation time after mixing with proteinase K for 36 h at 55°C, meanwhile, adding proteinase K every 12 h. Depending on the size of the tumor sample, the RNA ranged from 0.02 to 2 μg (Nanodrop2000, Thermo Scientific, Wilmington, DE, USA). The RNA isolation of the positive control cell line (U87δ) was performed with the Absolute RNA Wash Solution (Applied Biosystems, Carlsbad, CA, USA). The reverse transcription was accomplished using the SuperScript® II Reverse Transcriptase (Invitrogen) according to the manufacturer’s protocol. The entire cDNA sample was treated with Ribonuclease H (Invitrogen, Ghent, Belgium) to eliminate the residual RNA after reverse transcription.

Two pairs of primers for EGFRvIII were derived from the previous reference to perform a hemi-nested PCR (19) with some modifications. For the first step PCR, a forward primer GAGCT CTTCGGGGAGCAG and a reverse primer TCCTCCATCTCA TAGCTGTCG were used to generate a 178 bp fragment that span the junctions of the deletion c.158_1136del. A standard PCR Master mix (25 μl in total) is composed of cDNA (1 μl), 1X PCR buffer, 1 μg/μl bovine serum albumin (BSA), 0.8 mM dNTPs, 0.025 U/μl Taq DNA polymerase (Qiagen, 5 U/μl) and 2 ng/μl of each primer. The reaction was run for 35 cycles denaturation at 94°C for 1 min, annealing at 64°C for 1 min and extension at 72°C for 1 min. During the second step, a 131 bp fragment was amplified 25 cycles using 1 μl of product from the first step PCR with the forwards primer GAGCTCTTCGGGG AGCAG and the reverse primer GTGATCTGTCACCACATA ATTACCTTTCT. All other PCR conditions were the same as step 1. The final PCR product was visualized on a 2% agarose gel and confirmed by sequencing (ABI 310 Genetic Analyzer, Applied Biosystems, Foster city, CA, USA) after purification with the High Pure PCR Product Purification kit (Roche, Penzberg, Germany). The analysis of each sample was performed in triplicate. EGFRvIV mutation analysis was performed with the same method as EGFRvIII.

 Immunohistochemistry of PTEN

PTEN expression was evaluated by immunohistochemistry on 4 μm FFPE tissue sections by using a rabbit IgG monoclonal antibody (1:100 dilution, PTEN, 138G6, Cell Signaling Technology Inc., Beverly, MA, USA) and an anti-rabbit IgG secondary antibody (ultraView Universal DAB Detection Kit, Ventana Medical Systems Inc., Tucson, AZ, USA) according to the manufacturer’s protocol. Immunoreactivity was visualized with a DAB solution provided in the kit (ultraView Universal DAB Detection Kit, Ventana Medical Systems Inc.). Positive controls were visualized on the same sections with epithelial cells and neurons. PTEN staining was both nuclear and cytoplasmic and was evaluated with a two-score system including intensity and percentage of positive cells as described (37).

 Clinical data and survival analysis

Clinical information was collected from each patient to investigate possible correlation between EGFRvIII mutation status and clinical parameters including glioma WHO grade, age, date of birth, date of initial diagnosis and of recurrence, date of progression and date of death or last contact. Kaplan-Meier survival analysis was used to examine the correlation between molecular baseline factors and survival data. We also analyzed the association between EGFRvIII, EGFRvIV, PTEN expression, EGFR amplification and IDH1 mutation.

 Results Analysis of EGFR gene amplification, EGFRvIII-, EGFRvIV-RNA expression, and PTEN-protein expression and IDH1 mutation status

EGFR amplification, EGFRvIII-, and EGFRvIV expression were detected in, respectively 19/35 (54%), 11/35 (31%) and 7/35 (20%, EGFRvIVa in 5/7 and EGFRvIVb in 2/7) of the gliomas (Fig. 1, Table I). EGFRvIII and EGFRvIV expression were exclusively found in patients with an EGFR amplification (11/19, 58%; 7/19, 37%). EGFRvIII was most frequently found in de novo GBs (9/26, 35%), and less frequently in secondary GBs and grade II or III glioma (2/9, 22%). Likewise, EGFRvIV was detected in 6/26 (23%) de novo GB and 1/9 (11%) of the anaplastic astrocytoma.

IDH1 mutation was found in 6/35 (17%) patients (Table I) and correlated with a younger age at first diagnosis, and a histological diagnosis of low-grade or secondary GB. IDH1 mutation was only rarely found in association with an EGFR amplification or expression of EGFRvIII and EGFRvIV (2/19 patients with EGFR amplification, 1/11 patients with EGFRvIII and 0/7 patients with EGFRvIV were found with a concomitant IDH1 mutation, Table II).

Strong positive IHC staining for PTEN expression was observed in 6 out of the 31 tested gliomas (Table I; Fig. 2) and found only in WHO grade IV gliomas (5/6 de novo GB and 1/6 secondary GB). Of these 6 patients with a PTEN positive de novo GB, 4 had an EGFR amplification, two of which also expressed EGFRvIII, none of them had EGFRvIV and all 6 patients had an IDH1 wild-type status (Table II). No significant correlation was found between PTEN expression and clinical baseline characteristics such as age, gender and performance status.

 Correlation between molecular markers and the survival of patients treated with cetuximab

At the time of this analysis, 34 out of 35 patients died, all because of tumor progression; one patient was lost to follow-up. The median overall survival (OS) and median progression free survival (PFS) from the time of recruitment to the clinical trial were respectively 4.8 months (95% CI: 3.9–5.6) and 1.8 months (95% CI: 1.5–2.0) (Table II).

In our previous report on this phase II trial, EGFR amplification was found to correlate with a numerical superior PFS and OS in patients treated with cetuximab (34). In this updated subgroup analysis, the correlation between EGFR amplification and superior survival of patients was still present for PFS [median PFS 2.10 in patients with EGFR amplification vs. 1.63 in patients with wild-type EGFR (p=0.09)] (Fig. 3A), however, was no longer found for OS (median OS 4.73 in patients with EGFR amplification vs. 4.80 in patients with wild-type EGFR, p=0.69). A numerically worse survival (PFS and OS) was observed for patients with expression of EGFRvIII but this difference did not reach the level of statistical significance [median PFS of 1.63 vs. 1.93 months (p=0.21) and median OS of 3.27 vs. 4.93 months (p=0.21)] (Fig. 3B and C). A better PFS and OS were found for patients with EGFR amplification lacking EGFRvIII expression [median PFS of 3.03 vs. 1.63 months (p=0.006); median OS of 5.57 vs. 3.97 months (p=0.12)] (Fig. 3D and E). When analyzed within the cohort of patients with EGFR amplification (n=19), expression of EGFRvIII correlated significantly with a worse outcome in survival [median PFS 1.63 vs. 3.03 months (p=0.01); median OS 3.27 vs. 5.57 months (p=0.08)] (Fig. 3F and G).

In univariate analysis, EGFRvIV mutation and PTEN expression were not correlated with the survival of the total population or within the subgroup of EGFR-amplified GBs.

 Discussion

In this study of 35 patients with recurrent high-grade gliomas treated with the EGFR monoclonal antibody cetuximab, we find that EGFRvIII/vIV expression is restricted to patients with EGFR amplification, confirming prior reports in the literature. EGFRvIII and EGFRvIV expression were rarely found in patients with an IDH1 mutation (1/6 and 0/6), again confirming the previous reports on the association of IDH1 mutation with WHO grade II and III glioma and secondary GB (3) and EGFR amplification/mutation with de novo GB (38).

Overall treatment with cetuximab has low activity against recurrent GB but shows a trend towards a higher activity in patients with EGFR-amplified GB, as was reported in our initial clinical study report (34). In this molecular sub-study we investigated the potential influence of specific EGFR-mutants and found that the expression of EGFRvIII correlated with a significantly worse survival in the cohort of patients with an EGFR amplification in our study. Similar observations have been reported previously (4). Since we observed that, the PFS of patients treated with cetuximab was significantly superior in patients with EGFR gene amplification but without EGFRvIII expression, we hypothesize that EGFR amplification without EGFRvIII may identify a subpopulation with a higher sensitivity for cetuximab. Given the single-arm study design, we however cannot exclude a naturally worse prognosis of EGFRvIII mutant GB among patients with EGFR-amplified tumors.

Although it was reported that cetuximab showed effective inhibition to EGFR CTD deletion mutation in glioblastoma cells and animal models (17), we did not find a correlation between EGFRvIV deletion and survival of patients in our study in total population or any sub-cohort. We can however not exclude that this is related to the small sample size of patients with an EGFRvIV mutated GB in our study.

In the literature, PTEN expression detected by IHC has been reported in about 62% of primary glioma (39) and in 17% of recurrent GB (40). PTEN expression as detected by IHC is also more frequently found in low-grade glioma as compared to high-grade glioma. We detected a positive PTEN expression in 21% of high-grade glioma (in 19% of the whole population), which is comparable with the data in the literature. It was previously reported that coexpression of EGFRvIII and PTEN was a predictor for response to EGFR inhibitors in patients with recurrent GB (25). In this study only two patients were found with combined EGFRvIII and PTEN expression making it impossible to assess this correlation. A study with larger sample size would be needed to assess the role of EGFRvIII and PTEN in survival of glioma patients treated with cetuximab at recurrence.

In summary, within the recurrent glioma patients who were treated with cetuximab we have confirmed that EGFR mutation is exclusively present in patients with EGFR amplification. In addition, we have found a particularly favorable survival for the sub-group of patients with EGFR amplification, but without EGFRvIII expression. Our study supports further documentation of both the glioma EGFRvIII expression and amplification status in studies with cetuximab.

This study was supported by the Free University Brussels (VUB)/the Chinese Scholarship Council (CSC) PhD program. We gratefully acknowledge the supply of U87/EGFRvIII cell from Professor Webster Cavenee (Ludwig Institute for Cancer Research, University of California, San Diego, CA, USA). We thank Mr. Kurt De Neef (Laboratory of Molecular Oncology, Free University Brussels, Belgium), Mr. Pascal Verhavert, Mr. Tim Walravens and Miss Sara Laceur (Pathology Department, University Hospital Brussels, Belgium) for their technical help. We also thank Miss Katrien Van den Bossche (data manager, University Hospital Brussels, Belgium) for her assistance and help. Bart Neyns has received research funding from Merck.

 References StuppRHegiMEMasonWPvan den BentMJTaphoornMJJanzerRCLudwinSKAllgeierAFisherBBelangerKHauPBrandesAAGijtenbeekJMarosiCVechtCJMokhtariKWesselingPVillaSEisenhauerEGorliaTWellerMLacombeDCairncrossJGMirimanoffROEuropean Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and National Cancer Institute of Canada Clinical Trials GroupEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol104594662009 VerhaakRGHoadleyKAPurdomEWangVQiYWilkersonMDMillerCRDingLGolubTMesirovJPAlexeGLawrenceMO’KellyMTamayoPWeirBAGabrielSWincklerWGuptaSJakkulaLFeilerHSHodgsonJGJamesCDSarkariaJNBrennanCKahnASpellmanPTWilsonRKSpeedTPGrayJWMeyersonMGetzGPerouCMHayesDNCancer Genome Atlas Research NetworkIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1Cancer Cell17981102010 YanHParsonsDWJinGMcLendonRRasheedBAYuanWKosIBatinic-HaberleIJonesSRigginsGJFriedmanHFriedmanAReardonDHerndonJKinzlerKWVelculescuVEVogelsteinBBignerDDIDH1 and IDH2 mutations in gliomasN Engl J Med3607657732009 ShinojimaNTadaKShiraishiSKamiryoTKochiMNakamuraHMakinoKSayaHHiranoHKuratsuJOkaKIshimaruYUshioYPrognostic value of epidermal growth factor receptor in patients with glioblastoma multiformeCancer Res63696269702003 EkstrandAJJamesCDCaveneeWKSeligerBPetterssonRFCollinsVPGenes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivoCancer Res51216421721991 WikstrandCJMcLendonREFriedmanAHBignerDDCell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIIICancer Res57413041401997 EkstrandAJLongoNHamidMLOlsonJJLiuLCollinsVPJamesCDFunctional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplificationOncogene9231323201994 HuangPHXuAMWhiteFMOncogenic EGFR signaling networks in gliomaSci Signal2re62009 WheelerSESuzukiSThomasSMSenMLeeman-NeillRJChioseaSIKuanCTBignerDDGoodingWELaiSYGrandisJREpidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activationOncogene29513551452010 NishikawaRJiXDHarmonRCLazarCSGillGNCaveneeWKHuangHJA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicityProc Natl Acad Sci USA91772777311994 TangCKGongXQMoscatelloDKWongAJLippmanMEEpidermal growth factor receptor vIII enhances tumorigenicity in human breast cancerCancer Res60308130872000 TheysJJuttenBDuboisLRouschopKMChiuRKLiYPaesmansKLambinPLammeringGWoutersBGThe deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironmentRadiother Oncol923994042009 SokJCCoppelliFMThomasSMLangoMNXiSHuntJLFreilinoMLGranerMWWikstrandCJBignerDDGoodingWEFurnariFBGrandisJRMutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targetingClin Cancer Res12506450732006 EkstrandAJSugawaNJamesCDCollinsVPAmplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tailsProc Natl Acad Sci USA89430943131992 FrederickLEleyGWangXYJamesCDAnalysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elementsNeuro Oncol21591632000 PinesGHuangPHZwangYWhiteFMYardenYEGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanismOncogene29585058602010 ChoJPastorinoSZengQXuXJohnsonWVandenbergSVerhaakRCherniackADWatanabeHDuttAKwonJChaoYSOnofrioRCChiangDYuzaYKesariSMeyersonMGlioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapiesCancer Res71758775962011 FrederickLWangXYEleyGJamesCDDiversity and frequency of epidermal growth factor receptor mutations in human glioblastomasCancer Res60138313872000 YoshimotoKDangJZhuSNathansonDHuangTDumontRSeligsonDBYongWHXiongZRaoNWintherHChakravartiABignerDDMellinghoffIKHorvathSCaveneeWKCloughesyTFMischelPSDevelopment of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samplesClin Cancer Res144884932008 NewcombEWCohenHLeeSRBhallaSKBloomJHayesRLMillerDCSurvival of patients with glioblastoma multi-forme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genesBrain Pathol86556671998 SonnweberBDlaskaMSkvortsovSDirnhoferSSchmidTHilbeWHigh predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)J Clin Pathol592552592006 NietoYNawazFJonesRBShpallEJNawazSPrognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancerJ Clin Oncol25440544132007 HeimbergerABHlatkyRSukiDYangDWeinbergJGilbertMSawayaRAldapeKPrognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patientsClin Cancer Res11146214662005 AldapeKDBallmanKFurthABucknerJCGianniniCBurgerPCScheithauerBWJenkinsRBJamesCDImmunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significanceJ Neuropathol Exp Neurol637007072004 MellinghoffIKWangMYVivancoIHaas-KoganDAZhuSDiaEQLuKVYoshimotoKHuangJHChuteDJRiggsBLHorvathSLiauLMCaveneeWKRaoPNBeroukhimRPeckTCLeeJCSellersWRStokoeDPradosMCloughesyTFSawyersCLMischelPSMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med353201220242005 LiLDutraAPakELabrieJE3rdGersteinRMPandolfiPPRechtLDRossAHEGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumorsNeuro Oncol119212009 Haas-KoganDAPradosMDLambornKRTihanTBergerMSStokoeDBiomarkers to predict response to epidermal growth factor receptor inhibitorsCell Cycle4136913722005 Haas-KoganDAPradosMDTihanTEberhardDAJellumaNArvoldNDBaumberRLambornKRKapadiaAMalecMBergerMSStokoeDEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibJ Natl Cancer Inst978808872005 van den BentMJBrandesAARamplingRKouwenhovenMCKrosJMCarpentierAFClementPMFrenayMCamponeMBaurainJFArmandJPTaphoornMJTosoniAKletzlHKlughammerBLacombeDGorliaTRandomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034J Clin Oncol27126812742009 JeukenJSijbenAAlendaCRijntjesJDekkersMBoots-SprengerSMcLendonRWesselingPRobust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnosticsBrain Pathol196616712009 PatelDLahijiAPatelSFranklinMJimenezXHicklinDJKangXMonoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surfaceAnticancer Res27335533662007 EllerJLLongoSLHicklinDJCanuteGWActivity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiformeNeurosurgery51100510132002 EllerJLLongoSLKyleMMBassanoDHicklinDJCanuteGWAnti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivoNeurosurgery561551622005 NeynsBSadonesJJoosensEBouttensFVerbekeLBaurainJFD’HondtLStrauvenTChaskisCIn’t VeldPMichotteADe GreveJStratified phase II trial of cetuximab in patients with recurrent high-grade gliomaAnn Oncol20159616032009 LouisDNOhgakiHWiestlerODCaveneeWKBurgerPCJouvetAScheithauerBWKleihuesPThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol114971092007 LvSTeugelsESadonesJQuartierEHuylebrouckMDu FourSLe MercierMDe WitteOSalmonIMichotteADe GreveJNeynsBCorrelation between IDH1 gene mutation status and survival of patients treated for recurrent gliomaAnticancer Res31445744632011 LoupakisFPollinaLStasiIRuzzoAScartozziMSantiniDMasiGGrazianoFCremoliniCRulliECanestrariEFunelNSchiavonGPetriniIMagnaniMToniniGCampaniDFlorianiICascinuSFalconeAPTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerJ Clin Oncol27262226292009 MasonWPCairncrossJGInvited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomasNeurology713653732008 FultsDPedoneCImmunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomasNeuro Oncol271792000 de GrootJFGilbertMRAldapeKHessKRHannaTAIctechSGrovesMDConradCColmanHPuduvalliVKLevinVYungWKPhase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastomaJ Neurooncol9089972008 Figures and Tables

PCR product migration pattern of EGFRvIII corresponding to the EGFRvIII with negative and positive control on 2% agarose gel.

Immunohistochemistry images of PTEN. (A and B) PTEN negative and positive staining on glioma tissues.

Kaplan-Meier survival estimates (p-value according to the Log-rank test). (A) Progression free survival (PFS) from the time of cetuximab treatment on EGFR amplification status in the global study population (p=0.09), solid line, EGFR amplification; dash line, EGFR wild-type; +, censored. (B and C) PFS and OS from the time of treatment of cetuximab in global population EGFRvIII status (p=0.21 and 0.21), solid line, EGFRvIII negative; dash line, EGFRvIII positive; +, censored. (D and E) PFS and OS from the time of treatment of cetuximab in global population based on EGFR amplification/EGFRvIII status (p=0.006 and 0.12), solid line, EGFR amplification without EGFRvIII; dash line, others; +, censored. (F and G) PFS and OS from the time of treatment of cetuximab in cohort of patients with EGFR amplification based on EGFRvIII status (p=0.01 and 0.08), solid line, EGFRvIII negative; dash line, EGFRvIII positive; +, censored.

Summary of clinical and molecular characteristics.

Characteristic (N=35) N
Sex, M/F 22/13
Median age, range 54, 33–73
Histology at first diagnosis
  WHO grade II and III glioma 9
  WHO grade IV, de novo GB 26
Histology at recurrence
  WHO grade II and III glioma 3
  WHO grade IV, secondary GB 6
  WHO grade IV, de novo GB 26
KPS at recurrence
  100 3
  90–80 10
  70–60 22
EGFR amplification status
  Amplification 19
  Wild-type 16
EGFRvIII status
  Mutation 11
  Wild-type 24
EGFRvIV status
  Mutation 7
  Wild-type 28
IDH1 status
  Mutation 6
  Wild-type 29
PTEN status (N=31)
  Positive 6
  Negative 25

N, number of patients; GB, glioblastoma; EGFRvIII, epidermal growth factor receptor variant III; EGFRvIV, epidermal growth factor receptor variant IV; IDH1, isocitrate dehydrogenase 1; PTEN, phosphatase and tensin homologue.

Correlation between molecular markers.

EGFRvIII
+ −
IDH1 mutation IDH1 mutation
+ − + −
N=31 EGFR amplification
  + PTEN + 0 2 0 2
− 1 8 1 5
  − PTEN + 0 0 0 2
− 0 0 2 8
N=35 EGFR amplification
  + EGFRvIV + 0 5 0 2
− 1 5 1 5
  − EGFRvIV + 0 0 0 0
− 0 0 4 12

N, number of patients available; EGFRvIII, epidermal growth factor receptor variant III; EGFRvIV, epidermal growth factor receptor variant vIV; IDH1, isocitrate dehydrogenase 1, + mutation, − wild-type; PTEN, phosphatase and tensin homologue, + expression, − loss.

Correlation between EGFRvIII status and PFS or OS after cetuximab treatment in different patients’ cohorts.

N PFS (months) OS (months)
Total pts. cohort 35
Media (95% CI: range) 1.83 (1.56, 2.09) 4.80 (3.95, 5.64)
EGFR amplification
  Pts. with EGFR amplification 2.10 4.73
  Pts. without EGFR amplification 1.63 4.80
  P-value 0.09 0.69
EGFRvIII
  Pts. with EGFRvIII 11 1.63 3.27
  Pts. without EGFRvIII 24 1.93 4.93
  P-value 0.21 0.21
EGFR amplification and EGFRvIII
  Pts. with EGFR amplification but without EGFRvIII 8 3.03 5.57
  Others pts. 27 1.63 3.97
  P-value 0.006 0.12
Pts. with EGFR amplification cohort 19
Media (95% CI: range) 2.10 (1.67, 2.52) 4.73 (3.69, 5.76)
EGFRvIII
  Pts. with EGFRvIII 11 1.63 3.27
  Pts. without EGFRvIII 8 3.03 5.57
  P-value 0.01 0.08

N, number of patients; PFS, progression free survival; OS, overall survival from cetuximab treatment; Pts., patients; EGFRvIII, epidermal growth factor receptor variant III; PTEN, phosphatase and tensin homologue.